Skip to main content
main-content
Erschienen in: American Journal of Clinical Dermatology 5/2022

05.08.2022 | COVID-19 | Original Research Article

Curbing COVID-19 Vaccine Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the Vaccine Adverse Event Reporting System (VAERS) Database

verfasst von: Julianne M. Falotico, Amar D. Desai, Asghar Shah, Jose W. Ricardo, Shari R. Lipner

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Adverse reactions to the COVID-19 vaccines have been of interest since their emergency authorization. Cutaneous manifestations of the vaccines are not well studied. We aimed to characterize cutaneous reactions to the Moderna (mRNA-1273) and the Pfizer-BioNTech (BNT162b2) COVID-19 vaccines on a large, national scale.

Methods

The Vaccine Adverse Event Reporting System was filtered for cutaneous and hair and nail reactions to the COVID-19 vaccines. Patient demographics and past medical histories, vaccine manufacturer and dosing, symptom timing, reaction location, and patient outcomes were extracted from each report.

Results

As of December 24, 2021, there were 67,273 cutaneous reactions to all COVID-19 vaccines, with most patients receiving the Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines. The most common reactions overall were injection-site reaction, urticaria, and papular rash, with injection-site reaction more common after the Moderna (mRNA-1273) vaccine, and all other cutaneous reactions more common after the Pfizer-BioNTech (BNT162b2) vaccine. Patients with past histories of psoriasis, urticaria, and local site reactions to a vaccine were more likely to report these same symptoms after the COVID-19 vaccine.

Conclusion

Patients should be counseled about these potential dermatologic reactions to the COVID-19 vaccines. Most occur within the first few days after vaccination, and are mild and self-limiting. Patients should therefore be encouraged that it is safe to receive the COVID-19 vaccine from a dermatological perspective.
Literatur
1.
Zurück zum Zitat McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol. 2021;85(1):46–55. CrossRef McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol. 2021;85(1):46–55. CrossRef
2.
Zurück zum Zitat Shay DK. Safety monitoring of the Janssen (Johnson & Johnson) COVID-19 vaccine—United States, March–April 2021. MMWR Morbidity and mortality weekly report. 2021;70. Shay DK. Safety monitoring of the Janssen (Johnson & Johnson) COVID-19 vaccine—United States, March–April 2021. MMWR Morbidity and mortality weekly report. 2021;70.
3.
Zurück zum Zitat Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine. 2020. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine. 2020.
4.
Zurück zum Zitat Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020.
5.
Zurück zum Zitat Català A, Muñoz-Santos C, Galván-Casas C, et al. Cutaneous reactions after SARS-COV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases. Br J Dermatol. 2022;186(1):142–52. CrossRef Català A, Muñoz-Santos C, Galván-Casas C, et al. Cutaneous reactions after SARS-COV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases. Br J Dermatol. 2022;186(1):142–52. CrossRef
6.
Zurück zum Zitat Shimabukuro TT, Nguyen M, Martin D, et al. Safety monitoring in the vaccine adverse event reporting system (VAERS). Vaccine. 2015;33(36):4398–405. CrossRef Shimabukuro TT, Nguyen M, Martin D, et al. Safety monitoring in the vaccine adverse event reporting system (VAERS). Vaccine. 2015;33(36):4398–405. CrossRef
7.
Zurück zum Zitat Moro PL, Woo EJ, Marquez P, et al. Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011–2019. Vaccine. 2020;38(37):5923–6. CrossRef Moro PL, Woo EJ, Marquez P, et al. Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011–2019. Vaccine. 2020;38(37):5923–6. CrossRef
8.
Zurück zum Zitat Woo EJ, Moro PL. Postmarketing safety surveillance of quadrivalent recombinant influenza vaccine: reports to the vaccine adverse event reporting system. Vaccine. 2021;39(13):1812–7. CrossRef Woo EJ, Moro PL. Postmarketing safety surveillance of quadrivalent recombinant influenza vaccine: reports to the vaccine adverse event reporting system. Vaccine. 2021;39(13):1812–7. CrossRef
9.
Zurück zum Zitat Krajewski P, Matusiak J. Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine. J Eur Acad Dermatol Venereol. 2021;35(10): e632. PubMedPubMedCentral Krajewski P, Matusiak J. Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine. J Eur Acad Dermatol Venereol. 2021;35(10): e632. PubMedPubMedCentral
10.
Zurück zum Zitat Piccolo V, Russo T, Mazzatenta C, et al. COVID vaccine‐induced pustular psoriasis in patients with previous plaque type psoriasis. J Eur Acad Dermatol Venereol. 2022. Piccolo V, Russo T, Mazzatenta C, et al. COVID vaccine‐induced pustular psoriasis in patients with previous plaque type psoriasis. J Eur Acad Dermatol Venereol. 2022.
11.
Zurück zum Zitat Perna D, Jones J, Schadt CR. Acute generalized pustular psoriasis exacerbated by the COVID-19 vaccine. JAAD Case Rep. 2021;17:1–3. CrossRef Perna D, Jones J, Schadt CR. Acute generalized pustular psoriasis exacerbated by the COVID-19 vaccine. JAAD Case Rep. 2021;17:1–3. CrossRef
12.
Zurück zum Zitat Durmaz I, Turkmen D, Altunisik N, et al. Exacerbations of generalized pustular psoriasis, palmoplantar psoriasis, and psoriasis vulgaris after mRNA COVID‐19 vaccine: A report of three cases. Dermatologic Therapy.e15331. Durmaz I, Turkmen D, Altunisik N, et al. Exacerbations of generalized pustular psoriasis, palmoplantar psoriasis, and psoriasis vulgaris after mRNA COVID‐19 vaccine: A report of three cases. Dermatologic Therapy.e15331.
15.
Zurück zum Zitat Huang Y-W, Tsai T-F. Exacerbation of psoriasis following COVID-19 vaccination: report from a single center. Front Med. 2021;8:2768. Huang Y-W, Tsai T-F. Exacerbation of psoriasis following COVID-19 vaccination: report from a single center. Front Med. 2021;8:2768.
16.
Zurück zum Zitat Musumeci ML, Caruso G, Trecarichi AC, et al. Safety of SARS-CoV-2 vaccines in psoriatic patients treated with biologics: a real life experience. Dermatol Ther. 2022;35(1): e15177. CrossRef Musumeci ML, Caruso G, Trecarichi AC, et al. Safety of SARS-CoV-2 vaccines in psoriatic patients treated with biologics: a real life experience. Dermatol Ther. 2022;35(1): e15177. CrossRef
17.
Zurück zum Zitat Pitlick MM, Joshi AY, Gonzalez-Estrada A, et al., editors. Delayed systemic urticarial reactions following mRNA COVID-19 vaccination. Allergy and Asthma Proceedings; 2022: OceanSide Publications, Inc. Pitlick MM, Joshi AY, Gonzalez-Estrada A, et al., editors. Delayed systemic urticarial reactions following mRNA COVID-19 vaccination. Allergy and Asthma Proceedings; 2022: OceanSide Publications, Inc.
18.
Zurück zum Zitat Magen E, Yakov A, Green I, et al., editors. Chronic spontaneous urticaria after BNT162b2 mRNA (Pfizer-BioNTech) vaccination against SARS-CoV-2. Allergy & Asthma Proceedings; 2022. Magen E, Yakov A, Green I, et al., editors. Chronic spontaneous urticaria after BNT162b2 mRNA (Pfizer-BioNTech) vaccination against SARS-CoV-2. Allergy & Asthma Proceedings; 2022.
19.
Zurück zum Zitat Ramos CL, Kelso JM. “COVID Arm”: very delayed large injection site reactions to mRNA COVID-19 vaccines. J Allergy Clin Immunol Pract. 2021;9(6):2480–1. CrossRef Ramos CL, Kelso JM. “COVID Arm”: very delayed large injection site reactions to mRNA COVID-19 vaccines. J Allergy Clin Immunol Pract. 2021;9(6):2480–1. CrossRef
20.
Zurück zum Zitat Marcantonio‐Santa Cruz O, Vidal‐Navarro A, Pesqué D, et al. Pityriasis rosea developing after COVID‐19 vaccination. J Eur Acad Dermatol Venereol. 2021. Marcantonio‐Santa Cruz O, Vidal‐Navarro A, Pesqué D, et al. Pityriasis rosea developing after COVID‐19 vaccination. J Eur Acad Dermatol Venereol. 2021.
21.
Zurück zum Zitat Piccolo V, Bassi A, Argenziano G, et al. BNT162b2 mRNA COVID‐19 vaccine‐induced chilblain‐like lesions reinforces the hypothesis of their relationship with SARS‐CoV‐2. J Eur Acad Dermatol Venereol. 2021. Piccolo V, Bassi A, Argenziano G, et al. BNT162b2 mRNA COVID‐19 vaccine‐induced chilblain‐like lesions reinforces the hypothesis of their relationship with SARS‐CoV‐2. J Eur Acad Dermatol Venereol. 2021.
22.
Zurück zum Zitat Freeman EE, McMahon DE, Lipoff JB, et al. Pernio-like skin lesions associated with COVID-19: a case series of 318 patients from 8 countries. J Am Acad Dermatol. 2020;83(2):486–92. CrossRef Freeman EE, McMahon DE, Lipoff JB, et al. Pernio-like skin lesions associated with COVID-19: a case series of 318 patients from 8 countries. J Am Acad Dermatol. 2020;83(2):486–92. CrossRef
23.
Zurück zum Zitat Freeman EE, McMahon DE, Lipoff JB, et al. The spectrum of COVID-19-associated dermatologic manifestations: an international registry of 716 patients from 31 countries. J Am Acad Dermatol. 2020;83(4):1118–29. CrossRef Freeman EE, McMahon DE, Lipoff JB, et al. The spectrum of COVID-19-associated dermatologic manifestations: an international registry of 716 patients from 31 countries. J Am Acad Dermatol. 2020;83(4):1118–29. CrossRef
24.
Zurück zum Zitat Galván Casas C, Catala A, Carretero Hernández G, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183(1):71–7. CrossRef Galván Casas C, Catala A, Carretero Hernández G, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183(1):71–7. CrossRef
25.
Zurück zum Zitat McMahon DE, Kovarik CL, Damsky W, et al. Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: a registry-based study. J Am Acad Dermatol. 2022;86(1):113–21. CrossRef McMahon DE, Kovarik CL, Damsky W, et al. Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: a registry-based study. J Am Acad Dermatol. 2022;86(1):113–21. CrossRef
26.
Zurück zum Zitat Woo EJ, Mba-Jonas A, Dimova RB, et al. Association of receipt of the Ad26. COV2. S COVID-19 vaccine with presumptive Guillain-Barré syndrome, February-July 2021. JAMA. 2021;326(16):1606–13. CrossRef Woo EJ, Mba-Jonas A, Dimova RB, et al. Association of receipt of the Ad26. COV2. S COVID-19 vaccine with presumptive Guillain-Barré syndrome, February-July 2021. JAMA. 2021;326(16):1606–13. CrossRef
Metadaten
Titel
Curbing COVID-19 Vaccine Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the Vaccine Adverse Event Reporting System (VAERS) Database
verfasst von
Julianne M. Falotico
Amar D. Desai
Asghar Shah
Jose W. Ricardo
Shari R. Lipner
Publikationsdatum
05.08.2022
Verlag
Springer International Publishing
Schlagwort
COVID-19
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 5/2022
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-022-00715-x